MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 05-16-2026
Syneos Health Cost of Revenue 2011-2026 | SYNH
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Syneos Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.14 B | 3.99 B | 3.4 B | 3.65 B | 3.43 B | - | 1.21 B | 1.03 B | 884 M | 775 M | 679 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.14 B | 679 M | 2.32 B |
Quarterly Cost of Revenue Syneos Health
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.07 B | 1.09 B | - | 1.02 B | 1.03 B | 1.04 B | - | 1.03 B | 993 M | 945 M | - | 820 M | 806 M | 924 M | - | 914 M | 918 M | 887 M | - | 872 M | 847 M | 841 M | - | - | 295 M | 285 M | - | 292 M | 300 M | 316 M | - | 251 M | 248 M | 223 M | - | 220 M | 213 M | 203 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.09 B | 203 M | 675 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
2.91 B | $ 113.34 | -0.34 % | $ 34.5 B |  USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 3.76 | 57.11 % | $ 5 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
71 M | $ 20.33 | 1.47 % | $ 589 M | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 17.27 | 5.24 % | $ 522 M | USA |
 |
Guardant Health
GH
|
349 M | $ 117.3 | 2.03 % | $ 14.7 B | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 21.68 | 2.51 % | $ 1.16 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 114.73 | -0.32 % | $ 9.46 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 142.69 | 0.54 % | $ 22.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Lantheus Holdings
LNTH
|
600 M | $ 94.8 | -1.34 % | $ 6.4 B | USA |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
413 M | $ 8.82 | -0.9 % | $ 1.13 B | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Natera
NTRA
|
158 M | $ 204.79 | -0.06 % | $ 20.2 B | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 3.78 | -0.79 % | $ 350 M | USA |
 |
Personalis
PSNL
|
53.9 M | $ 8.32 | 4.59 % | $ 742 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.78 B | $ 26.85 | 0.45 % | $ 25.5 B |  Niderland |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 5.9 | 3.33 % | $ 246 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.7 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.41 | 2.52 % | $ 5.54 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 253.42 | -1.55 % | $ 21.1 B | USA |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 53.82 | 0.29 % | $ 3.22 B | USA |
 |
Trinity Biotech plc
TRIB
|
40.1 M | $ 0.62 | 2.58 % | $ 223 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Neogen Corporation
NEOG
|
473 M | $ 8.62 | -2.43 % | $ 1.87 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 192.24 | -0.78 % | $ 21.3 B | USA |
 |
Waters Corporation
WAT
|
363 M | $ 337.2 | -1.18 % | $ 20.1 B | USA |